# Nivalis Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nivalis-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Boulder, US
- Website: www.n30pharma.com
- Total disclosed funding: $10M
- Latest round: Series B (Jul 12, 2010)
- Investors on record: 3

## About

Nivalis Therapeutics focuses on developing innovative therapies targeting cystic fibrosis and other inflammatory lung diseases through proprietary small molecule inhibitors, aiming to improve patient outcomes and organ repair.Nivalis Therapeutics, headquartered in Boulder, US, was founded in 2007 to specialize in innovative therapies for cystic fibrosis. The company has undergone strategic pivots and has raised a total of USD 88.55 mn in funding, with its most recent deal being an IPO on June 17, 2015. The CEO of Nivalis is Charles Scoggin, whose previous entrepreneurial ventures have contributed to the company's strategic direction.Nivalis Therapeutics specializes in the development of disease-modifying therapies that target inflammatory lung diseases, particularly cystic fibrosis. Their primary offerings include proprietary small molecule inhibitors of GSNOR, aiming to enhance organ repair and regeneration by preserving intracellular GSNO levels. Their target market primarily includes patients with cystic fibrosis and healthcare providers, focusing on both North American expansion and growth into European markets as development progresses.For the most recent fiscal year 2023, Nivalis Therapeutics reported a revenue of USD 58.88 mn and an EBITDA of USD -51.73 mn. The company's revenue structure is anticipated to be supported by partnerships, milestone payments, and royalties from product sales upon market approval.Nivalis Therapeutics plans to leverage its recent funding of USD 88.55 mn from its IPO in June 2015 to accelerate the development of its innovative therapies for cystic fibrosis. The company aims to launch new products targeting additional inflammatory lung conditions in the coming years, expanding its reach into European markets by 2025. The recent funding will facilitate extensive clinical trials and potential collaborations with healthcare providers and pharmaceutical partners to ensure timely market entry of their products.

## Funding rounds

- Series B, Jul 12, 2010, $10M — Deerfield Capital Management, Bridger Capital, Deerfield Management

## Investors

- Deerfield Capital Management (https://capitalatlas.ai/funds/deerfield-capital-management) — Series B
- Bridger Capital — Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series B